Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Bone Mass Clear all

Conditions: Alagille Syndrome, Cholestasis, Biliary Atresia
Interventions: magnesium gluconate, magnesium sulfate; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 3 Years to 18 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Dental Diseases
Interventions: Dual-energy computed tomography scan; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Osteoporosis, Renal Osteodystrophy, Kidney Transplant; Complications
Interventions: Denosumab Inj 60 mg/ml, Placebo; Drug · Other
Lead sponsor: Thomas Nickolas, MD MS; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Chicago, Illinois • Evanston, Illinois • New York, New York

Conditions: Osteopenia, Osteoporosis
Interventions: Micronized Calcium Carbonate, Non-Micronized Calcium Carbonate, Vitamin D3; Dietary Supplement
Lead sponsor: Integrative Health Technologies, Inc.; Network
Eligibility: 21 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Williams Syndrome, Lipedema
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Postmenopausal Osteoporosis
Interventions: Teriparatide, Denosumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoporosis, Spinal Cord Injuries
Interventions: Romosozumab, Denosumab; Drug
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: West Orange, New Jersey • The Bronx, New York

Conditions: Hyperparathyroidism
Interventions: Alendronate 70mg weekly; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Marfan Syndrome
Interventions: Atenolol, Losartan; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 25 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bone Disease, Metabolic, Osteopenia, Osteoporosis, Post-Traumatic
Interventions: Pulsing electromagnetic field (PEMF); Device
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Osteoporosis
Interventions: No intervention element, observational study.; Other
Lead sponsor: Drexel University; Other
Eligibility: 20 Years to 50 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Uterine Fibroids, Endometriosis
Interventions: Relugolix Combination Tablet; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 120
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 98 more

Conditions: The Skeletal Effects of SSRIs
Interventions: Not listed
Lead sponsor: Chadi A. Calarge; Other
Eligibility: 15 Years to 20 Years
Enrollment: 287 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Postmenopausal Bone Loss, Breast Cancer
Interventions: Not listed
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cystic Fibrosis, Contraception
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 562 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 7 more

Conditions: BRCA1 Mutation, Breast Cancer, Breast Diseases, Breast Neoplasms, Breast Carcinoma, Neoplasms
Interventions: Denosumab, Placebo, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 25 Years to 55 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2033
U.S. locations: 47
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 38 more

Conditions: Prematurity, VLBW - Very Low Birth Weight Infant
Interventions: Prepod, Joint compression exercises; Other · Procedure
Lead sponsor: Asante Health System; Other
Eligibility: 32 Weeks to 36 Weeks
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Medford, Oregon

Conditions: Bone Health
Interventions: exercise, exercise and calcium; Behavioral
Lead sponsor: Creighton University; Other
Eligibility: 9 Years to 9 Years · Female only
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2007
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Osteoporosis
Interventions: Raloxifene, Zoledronic acid, Placebo oral pills, Placebo intravenous (i.v.) infusion; Drug
Lead sponsor: Novartis; Industry
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Phoenix, Arizona • Buena Park, California • Washington D.C., District of Columbia + 12 more

Conditions: Osteoporosis, Aging
Interventions: Vitamin D3, Calcium Citrate (Citracal); Dietary Supplement
Lead sponsor: Creighton University; Other
Eligibility: 57 Years and older · Female only
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Burn, Growth, Malnutrition
Interventions: Calcium,Vitamin D, Calcium, VitaminD, Sugar Pill; Dietary Supplement · Other
Lead sponsor: Kathy Prelack, PhD, RD; Other
Eligibility: 4 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Endometriosis, Dysmenorrhea, Dyspareunia
Interventions: Norethindrone Acetate (NA), GnRH Agonist (Lupron Depot); Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Down Syndrome
Interventions: Skeletal Status Assessment of a Down Syndrome Population; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Hypopituitarism, Hypogonadism, Thyroid Dysfunction, Bone Diseases, Metabolic
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 24 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease

Dual Energy Cone-Beam Computed Tomography (DE-CBCT) Assessment of Jaw Bone Density

The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients

A Study of Changes in Bone Mineral Density as a Function of Consuming Two Different Forms of Calcium Carbonate

Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study

Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration

Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI

The Effects of Alendronate After Cure of Primary Hyperparathyroidism

Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome

Electromagnetic Treatment For Bone Loss After Forearm Fracture

Determinants of Bone Mineral Density and Metabolic Syndrome in South Asian Indian Men

A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Do Serotonin Reuptake Inhibitors (SSRIs) Affect Bone Mass in Adolescents

A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer

Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation

Self Regulated Physical Activity and Bone Growth Enhancement in Premature Infants

Study to Determine How Exercise and Calcium Affect Pubertal Bone

Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

Vitamin D Supplementation in Older Women

Bone Mineral Density, Body Composition and Growth Following Severe Burn Injury

Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

Assessment of Bone Density and Bone Turnover Markers in Patients With Down Syndrome and Comparison to the Ts65Dn Model

Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients